Metabolic

Featured Article

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Latest Features

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Although many of the newer antidiabetic drugs have demonstrated favorable outcomes in clinical trials, some have also been associated with increased risk of adverse CV outcomes.

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Latest News

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.

Lorcaserin Facilitates Weight Loss Without Increasing Risk of Major CV Events

Lorcaserin Facilitates Weight Loss Without Increasing Risk of Major CV Events

In the CAMELLIA-TIMI 61 study, 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors were randomized to receive either lorcaserin 10mg twice daily or placebo.

Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD

Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD

The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.

Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline

Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline

While certain biomarkers are associated with eGFR decline in patients with type 2 diabetes, their predictive power is low.

Casual Glucose Concentrations Predict Post-Surgical Myocardial Injury

Casual Glucose Concentrations Predict Post-Surgical Myocardial Injury

Glucose concentration assessment before noncardiac surgery may help clinicians predict the risk for postoperative myocardial injury in patients with and without diabetes.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

Improving Sleep Quality May Reduce Cardiovascular Risk in Bipolar Disorder

Improving Sleep Quality May Reduce Cardiovascular Risk in Bipolar Disorder

The relationship between circadian rhythm and sleep measures and components of metabolic syndrome in patients with bipolar disorder.

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.

Results From Long-Term Cardiovascular Safety Study of Lorcaserin Announced

Results From Long-Term Cardiovascular Safety Study of Lorcaserin Announced

Approximately 12,000 patients took part in the CAMELLIA-TIMI 61 trial in which participants were randomized to either lorcaserin HCl 10mg twice daily or placebo.

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Investigators examined the association between hypoglycemia and cardiovascular outcomes and death.

Sign Up for Free e-Newsletters